Format

Send to

Choose Destination
See comment in PubMed Commons below
Nefrologia. 2012 May 14;32(3):385-8. doi: 10.3265/Nefrologia.pre2012.Feb.11332.

Infliximab in the treatment of amyloidosis secondary to Crohn's disease.

[Article in English, Spanish]

Author information

1
Hospital General Universitario Reina Sofía, Murcia, Spain. juanbecaro@gmail.com

Abstract

Secondary amyloidosis (AA) is a severe complication of progressed Crohn’s disease (CD) for which no effective treatment exists. We present the exceptional case of a 33 year-old male with moderate renal failure and proteinuria, who was simultaneously diagnosed with AA amyloid nephropathy and oligosymptomatic CD. He was treated with infliximab at 5mg/kg/8 weeks for 4 years, azathioprine at 1-1.5mg/kg/day (first year) and renin-angiotensin-aldosterone system blockers, with no complications. Treatment caused a decrease in proteinuria, improved renal function, and improved inflammatory parameters over time. Inspired by this case, we performed a review of the medical literature and found that infliximab could be a useful tool in the early treatment of amyloidosis secondary to CD.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ediciones Doyma, S.L.
    Loading ...
    Support Center